In short
Currently, there is 1 ongoing clinical trial investigating treatment options for Central Serous Chorioretinopathy, an eye condition where fluid builds up under the retina causing vision problems. This trial is examining the use of steroid eye drops to reduce fluid accumulation and improve vision in patients with the chronic form of this condition.
Clinical trial locations
Study on the Effects of Prednisolone Acetate and Placebo Eye Drops for Patients with Chronic Central Serous Chorioretinopathy
This trial is being conducted in the Netherlands and focuses on testing whether steroid eye drops can help patients with chronic Central Serous Chorioretinopathy. The study compares Pred Forte eye drops, which contain the active ingredient prednisolone acetate, with placebo eye drops to understand their effect on fluid buildup in the eye.
Main inclusion criteria:
- Patients must be 18 years or older
- Both men and women can participate
- Patients must have fluid visible on an OCT scan (a special imaging test for the eye) that has been present for 3 months or longer
- Patients should have noticed their vision has worsened
- Patients must be able to put eye drops in themselves
- Patients should have complex or severe chronic Central Serous Chorioretinopathy with specific signs of damage to the retina, such as areas of retinal pigment epithelium damage, multiple areas of fluid leakage, or other retinal changes visible on specialized eye scans
Main exclusion criteria:
- Patients without a confirmed diagnosis of Central Serous Chorioretinopathy
- Patients outside the specified age range
- Patients who are part of vulnerable populations requiring special protection or care
Focus and goal: The trial aims to determine whether Pred Forte eye drops can effectively reduce the fluid that accumulates in the eye in patients with chronic Central Serous Chorioretinopathy. Participants will use the eye drops for four weeks, and doctors will measure fluid levels in the eye using Optical Coherence Tomography before and after treatment. This imaging technique provides detailed pictures of the eye's structure and helps track changes in fluid levels. The study follows a structured approach: an initial eye examination confirms the condition, participants receive either the medication or placebo drops for four weeks, and then a follow-up examination measures any changes in fluid levels.
Investigational drug: Pred Forte is an eye drop containing prednisolone acetate, a type of corticosteroid. Steroids help reduce inflammation and, in this case, are being tested to see if they can decrease fluid accumulation under the retina. The medication works by binding to specific receptors in the body that help suppress inflammatory responses and reduce swelling in the eye.
Summary
Currently, only one clinical trial is actively recruiting patients with Central Serous Chorioretinopathy, taking place in the Netherlands. This trial specifically targets patients with the chronic form of the condition who have experienced persistent fluid buildup for at least three months. The focus is on evaluating a steroid-based eye drop treatment, Pred Forte, which may offer a new approach to managing this condition by reducing inflammation and fluid accumulation in the retina. The trial's structured four-week treatment period with careful monitoring through advanced imaging techniques demonstrates a methodical approach to understanding whether this medication can provide meaningful benefits for patients suffering from vision problems related to this condition.
